- Reaction score
- 214
Pretty much no human beings lose their hair because their diet has too much fat in itAfter PTD-DBM.. here comes
D-Threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (D-PDMP) (CAS 80938-69-8) what an animal!
anyway this was a study for atherosclerosis few years ago
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4557963/
so this means this is still being studied for various conditions, that's always good news but other interesting things are closer from us ..
the interesting thing could be to treat manifestations of cardiovascular disease. We know this occurs more often for people with androgenetic alopecia according to recent studies. hence taurine or aspirin shows some success for some people? Maybe just maybe... but taurine also acts on cortisol like we know so..Pretty much no human beings lose their hair because their diet has too much fat in it
PTD-DBM treats AA and I can't believe no one has synthesized the peptide yet and trialed it
we observed that chronic high-fat and high-cholesterol diet intake in a mouse model of atherosclerosis (ApoE−/−) decreases the level of ceramides and glucosylceramide. At the expense of increased levels of lactosylceramide due to an increase in the expression of lactosylceramide synthase (GalT-V). This is accompanied with neutrophil infiltration into dermis, and enrichment of tumor necrosis factor-stimulated gene-6 (TSG-6) protein. This causes skin inflammation, hair discoloration and loss, in ApoE−/− mice. Conversely, inhibition of glycosphingolipid synthesis, by D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (D-PDMP), unbound or encapsulated in a biodegradable polymer (BPD) reversed these phenotypes.
In the present work, we showed that in vivo deposition of a picomolar dose of miglustat applied directly to the respiratory epithelium efficiently corrects ion transport abnormalities of the F508del-CFTR protein. The response was characterized by an early and complete correction of both sodium and chloride conductances. When administered orally (20), correcting effects of miglustat on the F508del mouse nasal mucosa required a dose approximately 120-fold larger than the human therapeutic dose used in Gaucher disease (1,200 mg/kg/d to mice vs. ∼10 mg/kg/d or 200 mg three times a day to adult patients). The duration of the normalizing effect on chloride conductance could be related to the effective half-life of miglustat, reported to be 6.3 hours in humans (12). This is in keeping with a report that the correcting effect of the miglustat to CF cells in culture is time dependent; the effect of a final concentration of 100 μM progressively declined after 4 to 6 hours with a total loss of effect after 14 hours (22).
Great post as usual @pegasus2I'm surprised this didn't get more attention. GSL would seem to be involved in Androgenetic Alopecia.
Inhibition of glycosphingolipid synthesis reverses skin inflammation and hair loss in ApoE−/− mice fed western diet - PMC
Sphingolipids have been accorded numerous biological functions however, the effects of feeding a western diet (diet rich in cholesterol and fat) on skin phenotypes, and color is not known. Here, we observed that chronic high-fat and high-cholesterol ...www.ncbi.nlm.nih.gov
Unfortunately GSL synthase inhibition comes with some pretty rough sides, including reversible infertility. However, GSL inhibitor, miglustat, is very active topically. The following study is not relating to hair, but it demonstrates that local application of miglustat exerts significant positive effects which are only observed at oral doses far higher than what is normally administered. Perhaps local application could improve cell metabolism in the HF? If so, the dose required would be low, and there might not be any severe side effects.